Page 2 - Interferon Alpha News Today

Психолог по тревожным расстройствам объясняет, как не поддаться массовой панике на фоне негативных событий в мире.

© Javier Galeano/AP Medical students in laboratory of the Latin American School of Medicine in Havana. Its a medical school like no other: the largest of its kind in the world. The Latin American School of Medicine (ELAM) in Havana, Cuba hosts students from well over 100 countries and every year, dozens of American students are paid to go there to train as doctors. Paid, that is, by the Cuban government on the proviso that they return to the U.S. and serve underprivileged communities. General...

Industry > Industry monitor > Pharmaceuticals 23 April 2021 The Drug Controller General of India (DCGI) has granted Restricted Emergency Use Approval for Zydus Cadila’s Pegylated Interferon alpha-2b (PegIFN) or `Virafin’ for treating moderate Covid-19 infection in adults.  A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during Covid, Virafin will help patients recover faster and avoid much of t...

Zydus In a big boost to the national effort against COVID-19, Ahmedabad-based pharmaceutical major Zydus Cadila on Friday (23 April) announced that the company has received Restricted Emergency Use Approval (EUA) from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN,) in treating moderate COVID-19 infection in adults. The company has claimed that a single dose subcutaneous regimen of the Virafin developed by it can help patien...

April 23, 2021 Company claims the treatment reduces the hours of supplemental oxygen in the patients Cadila Healthcare Limited (Zydus Cadila) has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-19 infection in adults. Announcing the development, the company informed that the single dose subcutaneous regimen of the antiviral Virafin will make the treatment...

URL copied Image Source : AP A health worker prepares to administer the COVAXIN vaccine for COVID-19 to a man at an indoor stadium. (Representational image) Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadilas Pegylated Interferon alpha-2b, Virafin for treating moderate COVID-19 infection in adults. Earlier, Zydus Cadila announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b, PegiHep has shown promis...

Zydus Cadila seeks DCGI nod for use of PegiHep in Covid-19 treatment April 05, 2021 Phase-3 clinical trials showed promising results in treating Covid-19 In what could be termed a major breakthrough in the disease management of Covid-19, drug major Cadila Healthcare Limited (Zydus Cadila) has said that initial Phase-III clinical trials of Pegylated Interferon Alpha 2b, PegiHep, showed promising results in the treatment of the novel coronavirus. The interim results indicate that PegIFN, when ad...

Zydus COVID-19 drug shows promise in Phase 3 trials; seeks DCGI nod Over 91.15% of patients treated with PegIFN were found to be RT PCR negative by day 7 as compared to 78.90 per cent on the standard of care arm; PegIFN reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate COVID-19 patients BusinessToday.In | April 5, 2021 | Updated 12:51 IST Interim results show PegIFN could help patients recover faster, avoiding complications seen in the advanced stages Zydus Cad...

New Delhi (India) [India], April 5 (ANI): Pharmaceutical Company Zydus Cadila on Monday informed that it has sought approval of the Drugs Controller General of India (DGCI) for using its hepatitis drug for the treatment of coronavirus.

With the phase-3 clinical trials of its Pegylated Interferon Alpha 2b therapy, PegiHep, showing promising results, Cadila Healthcare Ltd (Zydus Cadila) has applied for an approval for additional indication with the Drugs Controller General of India (DCGI) for the use of PegIFN in the treatment of Covid-19. In what could be a breakthrough in the disease management of Covid-19, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoid much...